T1	Participants 204 254	patients with relapsing-remitting MS in a phase 2,
T2	Participants 443 558	Patients were eligible for the study if they had had two or more MS relapses in the 2-year period before enrollment
T3	Participants 560 633	Seventy patients with Expanded Disability Status Scale scores of 0 to 5.5
